Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Multi-million-euro win in Spanish lottery in doubt due to oversight - 2My Enterprising Excursion: Building a Startup
- 3Step into Nature: A Survey of \Handling Trails with Solace\ Climbing Shoes
- 4Insight: Pills, TikTok, weight-loss apps and the consumer-driven future of GLP-1s
- 5Rick Steves' Newest Guidebook Is A Fresh Perspective On Italy Spilling The Country's Secrets
- Step by step instructions to Guarantee the Strength and Life span of Your Pre-assembled Home
- Audits of the Top Science fiction Movies This Year
- Wisconsin judge sends Slender Man attacker back to mental health institution after group home escape
- ‘Integral part of our nation’: Herzog visits Franciscan Sisters in Jerusalem ahead of Christmas
- Some gifted dogs can learn new toy names by eavesdropping on owners
- Nvidia Share Price Could Be Hit Hard By Iran War
- 5 Wellbeing Applications Assist You With remaining Fit
- FDA updates risk classification for voluntary shredded cheese recall
- Ancient Egyptian pharaoh's boat is being reassembled in public at the Grand Egyptian Museum
